Abstract:Spinal cord injury (SCI) is a serious clinical situation for which no suitable drug therapy exists. SCI often results in paraplegia or quadriplegia and, apart from the personal trauma leads to huge costs to society for rehabilitation or day-to-day life support. Sensory motor dysfunction following SCI is mainly a consequence of the slowly progressing cord pathology after primary injury that worsens over tine. Thus, almost all sensory and motor nerve control and pathways passing through spinal cord and reflexes are compromised in SCI patients. As a result their peripheral nervous system, autonomic nervous function and central nervous system regulations are adversely affected. Experiments carried out in our laboratory show that various therapeutic agents, if given within 10 to 30 minutes after primary SCI could correct morphological changes to a certain extent. In these rat models of SCI reduction in cord pathology, e.g., bloodspinal cord barrier (BSCB) breakdown, edema formation and cell injury by the neuroprotective agents that also limited sensory motor dysfunction and improved functional behavior. However, these drugs if given beyond 30 minutes after SCI showed a markedly reduced neuroprotective efficacy. Thus, new strategies are needed to enhance neuroprotection in SCI to prevent structural and functional changes over longer periods of time. To that end our laboratory has initiated a series of investigations in which nanowired delivery of various neurotherapeutic agents are applied after different time periods of SCI, that resulted in a much better outcome than with the parent compounds under identical conditions. The superior neuroprotective activity of nanowired compound delivery could be due to a reduced metabolism of active compounds in the central nervous system (CNS) or by sustained release of the drug for longer times. In addition, nanowired drugs may penetrate the CNS faster and could reach widespread areas once entering the spinal cord. Thus, nanowired drug delivery to treat SCI may have potential therapeutic value. These aspects of nanowired drug delivery to enhance neuroprotection in SCI are discussed in this review based on our own investigations.

Zonisamide-loaded Triblock Copolymer Nanomicelles As a Novel Drug Delivery System for the Treatment of Acute Spinal Cord Injury.

Mechanics-Electro-Adaptive Multifunctional Bioactive Nanocomposites Hydrogel for Inducing Spinal Cord Regeneration

Zonisamide-loaded triblock copolymer nanomicelle as a controlled drug release platform for the treatment of oxidative stress -induced spinal cord neuronal damage

Drug-Loaded Zwitterion-Based Nanomotors for the Treatment of Spinal Cord Injury

Improving Functional Recovery after Severe Spinal Cord Injury by a Noninvasive Dual Functional Approach of Neuroprotection and Neuromodulation

Zeolitic imidazole framework-8 loaded gelatin methacryloyl microneedles: A transdural and controlled-release drug delivery system attenuates neuroinflammation after spinal cord injury

Novel multi-drug delivery hydrogel using scar-homing liposomes improves spinal cord injury repair.

A novel hydrogel-based combination therapy for effective neuroregeneration after spinal cord injury

Codelivery of minocycline hydrochloride and dextran sulfate via bionic liposomes for the treatment of spinal cord injury

Bioengineered Zinc Oxide Nanoparticle-Loaded Hydrogel for Combinative Treatment of Spinal Cord Transection

Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury.

Novel optimized drug delivery systems for enhancing spinal cord injury repair in rats

Preparation of a minocycline polymer micelle thermosensitive gel and its application in spinal cord injury

Synthesis and Characterization of a Silica-Based Drug Delivery System for Spinal Cord Injury Therapy

Supramolecular assemblies with spatio-temporal sequential drug delivery capability treat spinal cord injury via neuroprotection and immunoregulation

Sodium alginate and naloxone loaded macrophage-derived nanovesicles for the treatment of spinal cord injury

Combinational Protective Therapy for Spinal Cord Injury Medicated by Sialic Acid-Driven and Polyethylene Glycol Based Micelles.

Modified ZIF-8 Nanoparticles for Targeted Metabolic Treatment of Acute Spinal Cord Injury

Injectable Hydrogel System Incorporating Black Phosphorus Nanosheets and Tazarotene Drug for Enhanced Vascular and Nerve Regeneration in Spinal Cord Injury Repair

Targeted Repair of Spinal Cord Injury Based on miRNA‐124‐3p–Loaded Mesoporous Silica Camouflaged by Stem Cell Membrane Modified with Rabies Virus Glycoprotein

Long-Acting Heterodimeric Paclitaxel-Idebenone Prodrug-Based Nanomedicine Promotes Functional Recovery after Spinal Cord Injury